QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 1.0E-6
-- x --
-- x --
-- - --
$ 0.00 - $ 2.09
28,246
na
na
$ 0.63
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 us-stocks-likely-to-open-lower-after-a-strong-rally-lows-are-likely-in-and-better-times-are-coming-says-expert

U.S. stock futures fell on Tuesday after a stellar rally on Monday. Futures of major benchmark indices were trading lower in pr...

 accelerate-diagnostics-files-for-chapter-11-protection-to-sell-substantially-all-assets

To provide necessary funding during the Chapter 11 proceeding, Accelerate has received a commitment of up to $12.5 million in a...

 accelerate-diagnostics-submits-its-accelerate-wave-system-and-positive-blood-culture-gram-negative-test-kit-to-the-us-fda-for-510k-clearance

Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the su...

 accelerate-diagnostics-q4-sales-2800m-miss-3020m-estimate

Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly sales of $2.800 million which missed the analyst consensus estimate of ...

 accelerate-q4-revenue-of-117-vs-121m-yoy-163m-cash-ending-2024-3-rise-in-consumable-revenue-amid-pheno-capital-sales-decline

2024 Fourth Quarter and Full-Year Financial ResultsPreliminary revenue was approximately $11.7 million for the year, compared t...

 accelerate-diagnostics-q3-2024-gaap-eps-059-misses-047-estimate-sales-2975m-miss-3020m-estimate

Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate...

 accelerate-diagnostics-announces-fda-clearance-of-its-accelerate-arc-system-an-automated-platform-designed-to-fight-against-sepsis-and-antimicrobial-resistance

An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR)Enables rapid, automated microbial ide...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION